Bliss GVS Pharma Reaches 52-Week High of Rs. 181.35 with 42.53% Annual Return

Bliss GVS Pharma, a small-cap player in the pharmaceuticals and drugs industry, has recently reached a new 52-week high of Rs. 181.35 on January 1, 2025. The stock has shown strong performance, outperforming its sector by 7.79% today. Over the past six days, Bliss GVS Pharma has experienced consecutive gains, accumulating a total return of 11.29%.

The stock’s intraday high of Rs. 181.35 reflects a 10.14% increase for the day. Additionally, Bliss GVS Pharma is currently trading above its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, indicating a positive trend in its price movement.

In terms of annual performance, Bliss GVS Pharma has delivered a notable return of 42.53% over the past year, significantly outpacing the Sensex, which has recorded an 8.20% increase during the same period. The stock’s recent performance highlights its resilience and growth within the competitive pharmaceuticals sector.

Related Posts

  • Pharma
  • May 31, 2025
  • 185 views
Generic drugs can bring hope for SMA patients’

Dr Ann Agnes Mathew, a consultant paediatric neurologist and neuromuscular specialist based in Bengaluru, treats nearly 600 SMA patients from across India. In an interview with DH’s Udbhavi Balakrishna, she…

  • Pharma
  • May 31, 2025
  • 162 views
47% of pharma MOUs from VGGS 2024 commissioned

Gandhinagar:  The state govt said that 47% of MoUs signed in the pharmaceutical sector in the Vibrant Gujarat Global Summit (VGGS) 2024 have been commissioned. It said on Friday that…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

Generic drugs can bring hope for SMA patients’

Generic drugs can bring hope for SMA patients’

47% of pharma MOUs from VGGS 2024 commissioned

47% of pharma MOUs from VGGS 2024 commissioned

I-Sec downgrades Aurobindo Pharma to Add, target price Rs 1,330

I-Sec downgrades Aurobindo Pharma to Add, target price Rs 1,330

AstraZeneca gets CDSCO nod for lung cancer drug

AstraZeneca gets CDSCO nod for lung cancer drug